Recent Updates
Recently added Catalysts
BTSG Positive Sentiment Score: 80/100

Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution

Key Takeaway: Onco360 has been appointed as the national specialty pharmacy provider for IMKELDI (imatinib) Oral Solution, which is used to treat various forms of leukemia and other rare diseases. This partnership with Shorla Oncology aims to enhance patient access to this important oral medication. IMKELDI is designed to address administration challenges, particularly for pediatric patients, by offering a liquid formulation that facilitates accurate dosing.
Price reaction · baseline $58.27 (2026-06-02T16:29:00.000Z) · hit during market hours · 2 other BTSG headline(s) in the window, move may be shared
day 0 close · peak
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Onco360 selected as national pharmacy partner for IMKELDI.
  • IMKELDI provides an alternative formulation for imatinib tablets.
  • The partnership aims to improve patient access to cancer treatments.
  • Strawberry-flavored liquid formulation supports accurate dosing.

Full Press Release Details

Louisville, KY – June 2, 2026 – Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Shorla Oncology for IMKELDI ® (imatinib) Oral Solution, indicated for the treatment of newly diagnosed Philadelphia-positive (Ph+ CML) chronic myeloid leukemia, Ph+ CML in blast crisis, accelerated phase or chronic phase after interferon-alpha therapy, adult and pediatric patients with Ph+ ALL, myelodysplastic/myeloproliferative disease (MDS/MPD), aggressive systemic mastocytosis (ASM), Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL), Dermatofibrosarcoma Protuberans (DFSP), Kit+ Gastrointestinal Stromal Tumors (GIST), and adjuvant treatment of GIST. 1
“We are honored to partner with Shorla Oncology to support patient access to this important oral solution across a broad range of cancer and rare disease indications,” said Benito Fernandez, Chief Commercial Officer. “Providing a formulation that helps to address administration challenges for both adult and pediatric patients aligns with our commitment to ensure patients receive the therapy they need in a way that best supports adherence and outcomes.”
IMKELDI ® is a strawberry-flavored, liquid formulation designed to support accurate dosing and serves as an alternative to imatinib tablets.
Please read the full prescribing information for IMKELDI ® .
About Onco360 Oncology Pharmacy Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com .
Benito Fernandez, Chief Commercial Officer Benito.fernandez@onco360.com 516-640-1332
References [1]IMKELDI ® (Imatinib) [Package Insert]. Cambridge, MA. Shorla Oncology. 2024.

Frequently Asked Questions

What is IMKELDI used for?

IMKELDI is indicated for treating various cancers, including Ph+ CML and Ph+ ALL.

Who is the pharmacy partner for IMKELDI?

Onco360 has been selected as the national pharmacy partner for IMKELDI.

What is unique about IMKELDI's formulation?

IMKELDI is a strawberry-flavored liquid formulation designed for accurate dosing.

What does Onco360 aim to improve with IMKELDI?

Onco360 aims to enhance patient access and adherence to cancer therapies.

Last updated: Jun 2, 2026